DK2364137T3 - Pharmaceutical suspension - Google Patents
Pharmaceutical suspension Download PDFInfo
- Publication number
- DK2364137T3 DK2364137T3 DK09768284.3T DK09768284T DK2364137T3 DK 2364137 T3 DK2364137 T3 DK 2364137T3 DK 09768284 T DK09768284 T DK 09768284T DK 2364137 T3 DK2364137 T3 DK 2364137T3
- Authority
- DK
- Denmark
- Prior art keywords
- suspension
- pharmaceutical
- therapeutic agent
- typically
- molecular weight
- Prior art date
Links
- 239000007971 pharmaceutical suspension Substances 0.000 title claims description 33
- 239000000725 suspension Substances 0.000 claims description 115
- 239000003814 drug Substances 0.000 claims description 42
- 229940124597 therapeutic agent Drugs 0.000 claims description 40
- 229920001223 polyethylene glycol Polymers 0.000 claims description 37
- 239000000375 suspending agent Substances 0.000 claims description 31
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 28
- 239000013049 sediment Substances 0.000 claims description 22
- 239000004705 High-molecular-weight polyethylene Substances 0.000 claims description 18
- 239000002202 Polyethylene glycol Substances 0.000 claims description 17
- 229920005862 polyol Polymers 0.000 claims description 15
- 239000004599 antimicrobial Substances 0.000 claims description 14
- 150000003077 polyols Chemical class 0.000 claims description 14
- 239000002245 particle Substances 0.000 claims description 12
- 238000005189 flocculation Methods 0.000 claims description 11
- 230000016615 flocculation Effects 0.000 claims description 11
- 239000000243 solution Substances 0.000 claims description 11
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- 150000003856 quaternary ammonium compounds Chemical class 0.000 claims description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 8
- 239000004094 surface-active agent Substances 0.000 claims description 8
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 5
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 5
- 229960004224 tyloxapol Drugs 0.000 claims description 5
- 229920001664 tyloxapol Polymers 0.000 claims description 5
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical group O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 239000004327 boric acid Substances 0.000 claims description 4
- 229960000722 brinzolamide Drugs 0.000 claims description 4
- HCRKCZRJWPKOAR-JTQLQIEISA-N brinzolamide Chemical compound CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 HCRKCZRJWPKOAR-JTQLQIEISA-N 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- CEIJFEGBUDEYSX-FZDBZEDMSA-N tandospirone Chemical compound O=C([C@@H]1[C@H]2CC[C@H](C2)[C@@H]1C1=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 CEIJFEGBUDEYSX-FZDBZEDMSA-N 0.000 claims description 4
- 229950000505 tandospirone Drugs 0.000 claims description 4
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims description 3
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 claims description 3
- 229960002470 bimatoprost Drugs 0.000 claims description 3
- 229960003679 brimonidine Drugs 0.000 claims description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 3
- 229960003957 dexamethasone Drugs 0.000 claims description 3
- IAVUPMFITXYVAF-XPUUQOCRSA-N dorzolamide Chemical compound CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 IAVUPMFITXYVAF-XPUUQOCRSA-N 0.000 claims description 3
- 229960003933 dorzolamide Drugs 0.000 claims description 3
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 claims description 3
- 229960001160 latanoprost Drugs 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 claims description 3
- 229960003702 moxifloxacin Drugs 0.000 claims description 3
- QEFAQIPZVLVERP-UHFFFAOYSA-N nepafenac Chemical compound NC(=O)CC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1N QEFAQIPZVLVERP-UHFFFAOYSA-N 0.000 claims description 3
- 229960001002 nepafenac Drugs 0.000 claims description 3
- BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical group C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 229960004605 timolol Drugs 0.000 claims description 3
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical group CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 claims description 3
- 229960002368 travoprost Drugs 0.000 claims description 3
- 125000005619 boric acid group Chemical group 0.000 claims 1
- 239000004615 ingredient Substances 0.000 description 17
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 230000000845 anti-microbial effect Effects 0.000 description 5
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 5
- -1 timolol maleate) Chemical compound 0.000 description 5
- 101800004538 Bradykinin Proteins 0.000 description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 4
- 102100035792 Kininogen-1 Human genes 0.000 description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 3
- 150000001642 boronic acid derivatives Chemical class 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229940068968 polysorbate 80 Drugs 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- YUWPMEXLKGOSBF-GACAOOTBSA-N Anecortave acetate Chemical compound O=C1CC[C@]2(C)C3=CC[C@]4(C)[C@](C(=O)COC(=O)C)(O)CC[C@H]4[C@@H]3CCC2=C1 YUWPMEXLKGOSBF-GACAOOTBSA-N 0.000 description 2
- 102000010183 Bradykinin receptor Human genes 0.000 description 2
- 108050001736 Bradykinin receptor Proteins 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 229920002538 Polyethylene Glycol 20000 Polymers 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 229960001232 anecortave Drugs 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- MPVGZUGXCQEXTM-UHFFFAOYSA-N linifanib Chemical compound CC1=CC=C(F)C(NC(=O)NC=2C=CC(=CC=2)C=2C=3C(N)=NNC=3C=CC=2)=C1 MPVGZUGXCQEXTM-UHFFFAOYSA-N 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 229960004114 olopatadine Drugs 0.000 description 2
- JBIMVDZLSHOPLA-LSCVHKIXSA-N olopatadine Chemical compound C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 JBIMVDZLSHOPLA-LSCVHKIXSA-N 0.000 description 2
- 239000002997 ophthalmic solution Substances 0.000 description 2
- 229940100654 ophthalmic suspension Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000007745 plasma electrolytic oxidation reaction Methods 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- WLRMANUAADYWEA-NWASOUNVSA-N (S)-timolol maleate Chemical compound OC(=O)\C=C/C(O)=O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 WLRMANUAADYWEA-NWASOUNVSA-N 0.000 description 1
- QGBLCIBATKETJC-UHFFFAOYSA-N 3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane;manganese(2+) Chemical compound [Mn+2].O1B([O-])OB2OB([O-])OB1O2 QGBLCIBATKETJC-UHFFFAOYSA-N 0.000 description 1
- RFRMMZAKBNXNHE-UHFFFAOYSA-N 6-[4,6-dihydroxy-5-(2-hydroxyethoxy)-2-(hydroxymethyl)oxan-3-yl]oxy-2-(hydroxymethyl)-5-(2-hydroxypropoxy)oxane-3,4-diol Chemical compound CC(O)COC1C(O)C(O)C(CO)OC1OC1C(O)C(OCCO)C(O)OC1CO RFRMMZAKBNXNHE-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 101000748137 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 31 Proteins 0.000 description 1
- 101000759988 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 48 Proteins 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- 229920000289 Polyquaternium Polymers 0.000 description 1
- 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 102100025023 Ubiquitin carboxyl-terminal hydrolase 48 Human genes 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 229940008201 allegra Drugs 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000003868 ammonium compounds Chemical class 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 229920006318 anionic polymer Polymers 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229940031663 carbomer-974p Drugs 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229920000831 ionic polymer Polymers 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000002068 microbial inoculum Substances 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 229960005221 timolol maleate Drugs 0.000 description 1
- VLCLHFYFMCKBRP-UHFFFAOYSA-N tricalcium;diborate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]B([O-])[O-].[O-]B([O-])[O-] VLCLHFYFMCKBRP-UHFFFAOYSA-N 0.000 description 1
- NFMWFGXCDDYTEG-UHFFFAOYSA-N trimagnesium;diborate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]B([O-])[O-].[O-]B([O-])[O-] NFMWFGXCDDYTEG-UHFFFAOYSA-N 0.000 description 1
- WUUHFRRPHJEEKV-UHFFFAOYSA-N tripotassium borate Chemical compound [K+].[K+].[K+].[O-]B([O-])[O-] WUUHFRRPHJEEKV-UHFFFAOYSA-N 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12008108P | 2008-12-05 | 2008-12-05 | |
| PCT/US2009/066570 WO2010065730A2 (en) | 2008-12-05 | 2009-12-03 | Pharmaceutical suspension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2364137T3 true DK2364137T3 (en) | 2017-07-10 |
Family
ID=41562672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK09768284.3T DK2364137T3 (en) | 2008-12-05 | 2009-12-03 | Pharmaceutical suspension |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9707173B2 (enExample) |
| EP (1) | EP2364137B1 (enExample) |
| JP (1) | JP5661640B2 (enExample) |
| AR (1) | AR074423A1 (enExample) |
| AU (1) | AU2009322355B2 (enExample) |
| CA (1) | CA2745123C (enExample) |
| CY (1) | CY1119038T1 (enExample) |
| DK (1) | DK2364137T3 (enExample) |
| ES (1) | ES2630037T3 (enExample) |
| HR (1) | HRP20170959T1 (enExample) |
| HU (1) | HUE034662T2 (enExample) |
| LT (1) | LT2364137T (enExample) |
| PL (1) | PL2364137T3 (enExample) |
| PT (1) | PT2364137T (enExample) |
| SI (1) | SI2364137T1 (enExample) |
| TW (1) | TW201023912A (enExample) |
| WO (1) | WO2010065730A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8912236B2 (en) | 2009-03-03 | 2014-12-16 | Alcon Research, Ltd. | Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye |
| WO2010101971A1 (en) * | 2009-03-03 | 2010-09-10 | Alcon Research, Ltd. | Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye |
| MX2013000578A (es) * | 2010-07-21 | 2013-02-21 | Alcon Res Ltd | Composicion farmaceutica con caracteristicas de solubilidad incrementadas. |
| WO2012016569A1 (en) | 2010-08-05 | 2012-02-09 | Conrig Pharma Aps | Deuterated tandospirone derivatives as 5-ht1a receptor agonists |
| US9630909B2 (en) | 2013-06-27 | 2017-04-25 | Mylan Laboratories Ltd | Process for the preparation of nepafenac |
| JP6279395B2 (ja) * | 2014-05-01 | 2018-02-14 | 東亜薬品株式会社 | ブリンゾラミド懸濁性点眼液組成物の製造方法 |
| US11458041B2 (en) | 2015-10-08 | 2022-10-04 | Ocular Therapeutix, Inc. | Punctal plug and bioadhesives |
| CN108434116B (zh) * | 2017-02-16 | 2021-05-11 | 人福普克药业（武汉）有限公司 | 贝萨罗汀软胶囊及其制备方法 |
| RS65207B1 (sr) | 2017-07-14 | 2024-03-29 | Janssen Pharmaceutica Nv | Formulacije bedakvilina sa dugim delovanjem |
| GR1009419B (el) * | 2017-11-07 | 2018-12-14 | Φαρματεν Αβεε | Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει εναν συνδυασμο βρινζολαμιδης και βριμονιδινης και μεθοδος για την παρασκευη αυτου |
| TWI798452B (zh) * | 2019-06-17 | 2023-04-11 | 晶碩光學股份有限公司 | 隱形眼鏡產品 |
| CN113018271B (zh) * | 2019-12-25 | 2022-08-09 | 四川科瑞德制药股份有限公司 | 一种坦度螺酮药物组合物及其制备方法和用途 |
| CA3166738A1 (en) | 2020-02-06 | 2021-08-12 | Charles D. Blizzard | Travoprost compositions and methods for treating ocular diseases |
| EP4142664A4 (en) | 2020-04-27 | 2024-05-29 | Ocular Therapeutix, Inc. | METHODS FOR TREATING ALLERGIC CONJUNCTIVITIS |
| US20220105101A1 (en) | 2020-10-05 | 2022-04-07 | Somerset Therapeutics, Llc | Efficient brinzolamide and brimonidine compositions |
| US20220105100A1 (en) * | 2020-10-05 | 2022-04-07 | Somerset Therapeutics, Llc | Safe brinzolamide and brimonidine compositions with enhanced benzalkonium chloride content |
| CA3268120A1 (en) * | 2023-05-11 | 2024-11-14 | Akums Drugs & Pharmaceuticals Limited | OPHTHALMIC FORMULATION FREE OF BENZALKONIUM CHLORIDE |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3856919A (en) * | 1970-06-08 | 1974-12-24 | Burton Parsons Chemicals Inc | Ophthalmic solution |
| US4027020A (en) | 1974-10-29 | 1977-05-31 | Millmaster Onyx Corporation | Randomly terminated capped polymers |
| US3931319A (en) | 1974-10-29 | 1976-01-06 | Millmaster Onyx Corporation | Capped polymers |
| US4409205A (en) * | 1979-03-05 | 1983-10-11 | Cooper Laboratories, Inc. | Ophthalmic solution |
| US4525346A (en) | 1981-09-28 | 1985-06-25 | Alcon Laboratories, Inc. | Aqueous antimicrobial ophthalmic solutions |
| US4407791A (en) | 1981-09-28 | 1983-10-04 | Alcon Laboratories, Inc. | Ophthalmic solutions |
| US4836986A (en) | 1984-09-28 | 1989-06-06 | Bausch & Lomb Incorporated | Disinfecting and preserving systems and methods of use |
| US5037647A (en) | 1988-09-15 | 1991-08-06 | Alcon Laboratories, Inc. | Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride |
| US5461081A (en) | 1989-09-28 | 1995-10-24 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
| US5145643A (en) | 1990-01-05 | 1992-09-08 | Allergan, Inc. | Nonoxidative ophthalmic compositions and methods for preserving and using same |
| US5206267A (en) | 1991-05-09 | 1993-04-27 | Morton Shulman | Pain controlling composition and method of preparation |
| US5338732A (en) | 1991-06-18 | 1994-08-16 | Bristol-Myers Squibb Company | Megestrol acetate formulation |
| US5932572A (en) | 1992-02-21 | 1999-08-03 | Alcon Laboratories, Inc. | Topical anti-glaucoma compositions |
| US5300287A (en) | 1992-11-04 | 1994-04-05 | Alcon Laboratories, Inc. | Polymeric antimicrobials and their use in pharmaceutical compositions |
| ES2141775T3 (es) * | 1993-04-16 | 2000-04-01 | Wakamoto Pharma Co Ltd | Composicion medicinal a base de agua termicamente gelificante reversible. |
| EP0782850A4 (en) | 1994-10-13 | 1998-03-04 | Wakamoto Pharma Co Ltd | LYOPHILIZED PREPARATION FOR PRODUCING A REVERSIBLE THERMOGELING MEDICINAL WATER-BASED |
| AU718199B2 (en) | 1996-12-13 | 2000-04-06 | Alcon Laboratories, Inc. | Use of low molecular weight amino alcohols in ophthalmic compositions |
| JPH10287552A (ja) | 1997-04-11 | 1998-10-27 | Kobayashi Seiyaku Kogyo Kk | 滅菌されたアシクロビル水性懸濁点眼剤及びその製造方法 |
| ES2227331T3 (es) | 1997-07-29 | 2005-04-01 | Alcon Laboratories, Inc. | Soluciones de acondicionamiento para el cuidado de las lentes de contacto duras. |
| EP1213018A4 (en) * | 1999-09-06 | 2004-04-14 | Ono Pharmaceutical Co | AGENTS FOR THE PREVENTION AND TREATMENT OF EYE DISEASES |
| MXPA02003130A (es) | 1999-09-24 | 2004-04-21 | Alcon Inc | Formulaciones topicas en suspension que contienen ciprofloxacino y dexametasona. |
| JP2003533464A (ja) | 2000-05-15 | 2003-11-11 | フアルマシア・イタリア・エツセ・ピー・アー | 安定化ステロイド懸濁液 |
| JP2004504357A (ja) | 2000-07-26 | 2004-02-12 | アルコン，インコーポレイテッド | ポリマー性懸濁化剤を含有しない薬学的懸濁組成物 |
| JP3450805B2 (ja) * | 2000-08-08 | 2003-09-29 | わかもと製薬株式会社 | 水性医薬組成物 |
| US20040256749A1 (en) | 2000-12-22 | 2004-12-23 | Mahesh Chaubal | Process for production of essentially solvent-free small particles |
| US6743439B1 (en) * | 2001-06-27 | 2004-06-01 | Alcon, Inc. | Ophthalmic compositions containing copolymers of sulfonated styrene and maleic anhydride |
| EP1429780B1 (en) | 2001-09-21 | 2005-12-21 | Alcon, Inc. | Method of treating middle ear infections |
| US7001615B1 (en) | 2001-12-07 | 2006-02-21 | Alcon, Inc. | Sustained release ophthalmic, otic and nasal suspension |
| WO2004000284A1 (en) | 2002-06-21 | 2003-12-31 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions with improved dissolution |
| EP1638941B1 (en) | 2003-05-22 | 2010-06-02 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
| US20040235892A1 (en) | 2003-05-22 | 2004-11-25 | Yujia Dai | Indazole and benzisoxazole kinase inhibitors |
| US20050245497A1 (en) | 2004-04-08 | 2005-11-03 | Penfold Philip L | Treatment of ophthalmic conditions |
| TWI358290B (en) | 2004-12-02 | 2012-02-21 | Alcon Inc | Topical nepafenac formulations |
| TW200640443A (en) | 2005-02-23 | 2006-12-01 | Alcon Inc | Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors |
| CA2607608A1 (en) | 2005-05-10 | 2006-11-16 | Alcon, Inc. | Suspension formulations of nepafenac and other ophthalmic drugs for topical treatment of ophthalmic disorders |
| PL1906916T3 (pl) | 2005-05-10 | 2009-02-27 | Alcon Inc | Zawiesina do oczu obejmująca lek okulistyczny, poloksaminę i glikolowy środek regulujący toniczność, zastosowanie wymienionej kompozycji do wytwarzania leku do leczenia zaburzeń wzroku |
| US20070173538A1 (en) * | 2005-12-23 | 2007-07-26 | Alcon, Inc. | PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
| EP1962803A1 (en) | 2005-12-23 | 2008-09-03 | Alcon, Inc. | PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
| US20070249546A1 (en) | 2006-04-22 | 2007-10-25 | Sawaya Assad S | Ophthalmic and related aqueous solutions containing antifungal agents, uses therefor and methods for preparing them |
| WO2008076819A2 (en) | 2006-12-18 | 2008-06-26 | Altus Pharmaceuticals Inc. | Human growth hormone formulations |
| KR20100051811A (ko) | 2007-07-20 | 2010-05-18 | 알콘, 인코퍼레이티드 | 눈에 수용체 티로신 키나제 저해(ｒｔｋｉ) 화합물을 전달하기 위한 약제학적 제제 |
| EP2072564B1 (de) | 2007-12-19 | 2013-07-03 | Sika Technology AG | Einkomponentiger, feuchtigkeitshärtender Polymerschaum |
| JP5155767B2 (ja) | 2008-08-04 | 2013-03-06 | 国立大学法人大阪大学 | ガス検知素子 |
| WO2010101971A1 (en) | 2009-03-03 | 2010-09-10 | Alcon Research, Ltd. | Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye |
-
2009
- 2009-11-19 TW TW098139293A patent/TW201023912A/zh unknown
- 2009-11-30 AR ARP090104602A patent/AR074423A1/es unknown
- 2009-12-03 HU HUE09768284A patent/HUE034662T2/en unknown
- 2009-12-03 HR HRP20170959TT patent/HRP20170959T1/hr unknown
- 2009-12-03 PL PL09768284T patent/PL2364137T3/pl unknown
- 2009-12-03 SI SI200931678A patent/SI2364137T1/sl unknown
- 2009-12-03 US US12/630,399 patent/US9707173B2/en active Active
- 2009-12-03 EP EP09768284.3A patent/EP2364137B1/en active Active
- 2009-12-03 CA CA2745123A patent/CA2745123C/en active Active
- 2009-12-03 ES ES09768284.3T patent/ES2630037T3/es active Active
- 2009-12-03 AU AU2009322355A patent/AU2009322355B2/en not_active Ceased
- 2009-12-03 PT PT97682843T patent/PT2364137T/pt unknown
- 2009-12-03 DK DK09768284.3T patent/DK2364137T3/en active
- 2009-12-03 JP JP2011539693A patent/JP5661640B2/ja active Active
- 2009-12-03 LT LTEP09768284.3T patent/LT2364137T/lt unknown
- 2009-12-03 WO PCT/US2009/066570 patent/WO2010065730A2/en not_active Ceased
-
2017
- 2017-06-29 CY CY20171100695T patent/CY1119038T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR074423A1 (es) | 2011-01-19 |
| AU2009322355A1 (en) | 2010-06-10 |
| CY1119038T1 (el) | 2018-01-10 |
| PL2364137T3 (pl) | 2017-09-29 |
| TW201023912A (en) | 2010-07-01 |
| ES2630037T3 (es) | 2017-08-17 |
| US20100144719A1 (en) | 2010-06-10 |
| PT2364137T (pt) | 2017-07-10 |
| CA2745123C (en) | 2018-11-13 |
| EP2364137A2 (en) | 2011-09-14 |
| LT2364137T (lt) | 2017-06-26 |
| HRP20170959T1 (hr) | 2017-09-22 |
| WO2010065730A2 (en) | 2010-06-10 |
| EP2364137B1 (en) | 2017-03-29 |
| AU2009322355B2 (en) | 2015-11-05 |
| US9707173B2 (en) | 2017-07-18 |
| HUE034662T2 (en) | 2018-02-28 |
| SI2364137T1 (sl) | 2017-07-31 |
| JP2012511009A (ja) | 2012-05-17 |
| WO2010065730A3 (en) | 2011-04-14 |
| JP5661640B2 (ja) | 2015-01-28 |
| CA2745123A1 (en) | 2010-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2364137T3 (en) | Pharmaceutical suspension | |
| JP2012511009A5 (enExample) | ||
| WO2014204791A1 (en) | Ophthalmic lipophilic and hydrophilic drug delivery vehicle formulations | |
| EA036306B1 (ru) | Стабилизированные силикатные композиции и их применение в качестве антиперспирантных композиций | |
| JP6353365B2 (ja) | 水性液剤 | |
| JP5842593B2 (ja) | 眼科用組成物 | |
| JP5925823B2 (ja) | ヒアルロン酸又はその薬学的に許容される塩を含む保存組成物及び関連する方法 | |
| JP6177594B2 (ja) | 水性眼科組成物 | |
| RU2601115C2 (ru) | Офтальмологическая композиция с повышающей вязкость системой, содержащей два различных средства повышения вязкости | |
| AU2012245538B2 (en) | Ophthalmic composition with a viscosity enhancement system having two different viscosity enhancing agents | |
| JP5834427B2 (ja) | ソフトコンタクトレンズへの吸着抑制方法 | |
| JP2020506925A (ja) | 局所用組成物 | |
| WO2020240451A1 (en) | In-situ gelling nanoemulsion of brinzolamide | |
| ES3012007T3 (en) | Lipid-based ophthalmic composition for the treatment of dry eye | |
| US20200390722A1 (en) | Compositions and methods for the removal of ear wax | |
| WO2013049539A1 (en) | A method of blocking or trapping allergens | |
| WO2010120841A1 (en) | Aqueous ophthalmic compositions containing anionic therapeutic agents | |
| Jadhav et al. | MICONAZOLE LONG RETENTIVE OPHTHALMIC SUSPENSION DEVELOPED WITH SODIUM ALGINATE AND CARRAGEENAN POLYMER SYSTEM | |
| WO2013049538A1 (en) | Allergen nasal compositions |